Payment overview · 2025
General Payments
$874.44
44 reported records · 20 companies
Healthcare provider profile · identity verified
Christopher M Wicker, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEXINGTON, SC · NPI 1801912829
Verified facts
What the public records show
CMS Open Payments records show Christopher M Wicker, MD received $874.44 in general payments during 2025 across 44 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ingrezza, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $192.82 | 22.1% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.00 | 10.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.74 | 6.4% | 3 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $55.56 | 6.3% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $54.36 | 6.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.62 | 5.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.40 | 5.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.72 | 5.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.45 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.64 | 3.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.67 | 3.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.51 | 2.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.87 | 2.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.30 | 2.5% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $20.68 | 2.4% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $19.24 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.15 | 2.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.90 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.96 | 1.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.85 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $874.44 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.59 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $115.77 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $59.20 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.74 | 3 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $55.56 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $54.36 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.62 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $51.62 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.84 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.67 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.67 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.67 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.84 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.84 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 143 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 112 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
143 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
112 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
98 | 13 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
183 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 18 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
69 | 13 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 506 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 103 |
| Omeprazole | Omeprazole | 377 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 364 | 75 |
| Gabapentin | Gabapentin | 306 | 59 |
| Losartan Potassium | Losartan Potassium | 295 | 62 |
| Furosemide | Furosemide | 289 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 66 |
| Alprazolam | Alprazolam | 271 | 60 |
| Lorazepam | Lorazepam | 252 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 228 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 33 |
| Potassium Chloride | Potassium Chloride | 191 | 41 |
| Lisinopril | Lisinopril | 184 | 47 |
| Eliquis | Apixaban | 183 | 42 |
| Valsartan | Valsartan | 183 | 39 |
| Tramadol Hcl | Tramadol Hcl | 178 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 36 |
| Trazodone Hcl | Trazodone Hcl | 155 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 35 |
| Jardiance | Empagliflozin | 147 | 28 |
| Carvedilol | Carvedilol | 144 | 33 |
| Farxiga | Dapagliflozin Propanediol | 143 | 25 |
| Famotidine | Famotidine | 141 | 25 |
| Simvastatin | Simvastatin | 141 | 31 |
| Montelukast Sodium | Montelukast Sodium | 140 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 46 |
| Pregabalin | Pregabalin | 132 | 32 |
| Metformin Hcl | Metformin Hcl | 127 | 33 |
| Mirtazapine | Mirtazapine | 124 | 27 |
| Sertraline Hcl | Sertraline Hcl | 123 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 28 |
| Prednisone | Prednisone | 117 | 60 |
| Spironolactone | Spironolactone | 117 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 24 |
| Mounjaro | Tirzepatide | 112 | 13 |
| Memantine Hcl | Memantine Hcl | 104 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 100 | 79 |
| Quetiapine Fumarate | Quetiapine Fumarate | 100 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 20 |
| Trulicity | Dulaglutide | 98 | 13 |
| Allopurinol | Allopurinol | 97 | 21 |
| Clonazepam | Clonazepam | 96 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 94 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 35 |
| Ezetimibe | Ezetimibe | 90 | 28 |
| Atenolol | Atenolol | 88 | 22 |
| Bupropion Xl | Bupropion Hcl | 88 | 14 |
| Glipizide Er | Glipizide | 83 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 19 |
| Diazepam | Diazepam | 72 | 19 |
| Ramipril | Ramipril | 72 | suppressed |
| Torsemide | Torsemide | 72 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 70 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 18 |
| Synthroid | Levothyroxine Sodium | 70 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 69 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 11 |
| Donepezil Hcl | Donepezil Hcl | 64 | 16 |
| Meloxicam | Meloxicam | 64 | 18 |
| Xarelto | Rivaroxaban | 64 | 12 |
| Celecoxib | Celecoxib | 61 | 22 |
| Finasteride | Finasteride | 52 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 11 |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Lansoprazole | Lansoprazole | 49 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 17 |
| Temazepam | Temazepam | 49 | 12 |
| Ondansetron Odt | Ondansetron | 48 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 48 | 11 |
| Fluconazole | Fluconazole | 47 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 45 | 12 |
| Linzess | Linaclotide | 45 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 15 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 16 |
| Clonidine | Clonidine | 42 | suppressed |
| Estradiol | Estradiol | 42 | 11 |
| Levetiracetam | Levetiracetam | 42 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 14 |
| Glipizide | Glipizide | 41 | suppressed |
| Ramelteon | Ramelteon | 40 | suppressed |
| Colchicine | Colchicine | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Dutasteride | Dutasteride | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 32 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Lactulose | Lactulose | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | 11 |
| Baclofen | Baclofen | 34 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 28 |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Oxycontin | Oxycodone Hcl | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 30 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | 16 |
| Digoxin | Digoxin | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Praluent Pen | Alirocumab | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Phenytoin | Phenytoin | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Topiramate | Topiramate | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 22 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 18 |
| Permethrin | Permethrin | 21 | 12 |
| Sucralfate | Sucralfate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Nystatin | Nystatin | 20 | 16 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 14 |
| Fentanyl | Fentanyl | 16 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Xanax | Alprazolam | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 14 | 12 |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Celebrex | Celecoxib | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $874.44 · 44 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPVAXIVE, CLOTTRIEVER BOLD CATHETER, COMIRNATY, CeQur Simplicity, Cologuard Collection Kit, EVENITY, FARXIGA, GARDASIL 9, GVOKE HYPOPEN, INGREZZA, INJECTAFER, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error